Freeline

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. Freeline has developed a next generation AAV based gene therapy platform to provide treatments for a wide range of diseases like haemophilia B, Fabry and Gaucher Disease, which have previously been underserved and incurable. We are headquartered in the UK and we also have operations in Germany and the US. Freeline was founded in 2015 and builds upon the pioneering work by our Chief Scientific Officer, Professor Amit Nathwani, Professor of Haematology at UCL. Our pipeline of gene therapies has the potential to change the lives of people with inherited, systemic debilitating diseases. The pipeline reflects our ambition to provide curative treatments for as wide a range of chronic diseases as possible. With our liver-based investigational gene therapy technology, we aim to improve the lives of people with chronic systemic diseases and realise the potential of gene therapy treatments. If you are interested in joining our team and help make our life-changing vision a reality, go to our website for further information. Our mission: to be life changers. Please read our Community Guidelines before engaging with us on LinkedIn: https://www.freeline.life/about-us/freeline-social-media-community-engagement-guidelines/